Cabaletta Bio (CABA)
NASDAQ:CABA
Top Page
Cabaletta Bio
(NASDAQ:CABA)
Select Model
Select Model
Rating:50Neutral
Price Target:
$3.00
▲(1.35% Upside)
Action:ReiteratedDate:03/23/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and heavy ongoing cash burn), partially offset by positive corporate progress and financing/runway visibility. Technicals are mixed and valuation metrics are not supportive due to negative earnings and no dividend.
Positive Factors
Focused CAR T pipeline
Cabaletta’s concentrated focus on CAR T therapies targeting pathogenic B cells creates a durable product-market fit in autoantibody-driven diseases. A clear therapeutic niche and specialized platform increase the chance of clinical and commercial differentiation versus broader immunology developers, supporting sustained competitive positioning if trials succeed.
Negative Factors
No product revenue
Being pre-commercial with zero product revenue is a structural constraint: the business must convert clinical programs to approved therapies to generate recurring income. Until then Cabaletta remains dependent on external financing and partnerships, making long-term growth contingent on successful trial outcomes and commercialization execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused CAR T pipeline
Cabaletta’s concentrated focus on CAR T therapies targeting pathogenic B cells creates a durable product-market fit in autoantibody-driven diseases. A clear therapeutic niche and specialized platform increase the chance of clinical and commercial differentiation versus broader immunology developers, supporting sustained competitive positioning if trials succeed.
Read all positive factors
Cabaletta Bio (CABA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$329.52M
Dividend YieldN/A
Average Volume (3M)2.35M
Price to Earnings (P/E)―
Beta (1Y)4.04
Revenue GrowthN/A
EPS Growth-17.21%
CountryUS
Employees161
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.40
Shares Outstanding111,322,670
10 Day Avg. Volume2,066,840
30 Day Avg. Volume2,349,948
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-1.69
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.36
Forecast
1Y Price Target
$15.17Price Target Upside412.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.6
Revenue Forecast (FY)N/A
Cabaletta Bio Business Overview & Revenue Model
Company Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody r...
How the Company Makes Money
Cabaletta Bio is a pre-commercial, clinical-stage biotechnology company and does not currently generate product revenue from approved therapies (null for product sales). Its reported revenue has primarily come from collaboration-related payments, ...
Cabaletta Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.65M | -4.81M | -1.43M | -3.68M | -733.00K |
| EBITDA | -170.59M | -110.30M | -66.25M | -49.29M | -45.56M |
| Net Income | -167.86M | -115.86M | -67.67M | -52.98M | -46.29M |
Balance Sheet | |||||
| Total Assets | 165.08M | 185.05M | 253.65M | 116.97M | 126.34M |
| Cash, Cash Equivalents and Short-Term Investments | 133.60M | 163.96M | 241.25M | 106.55M | 122.22M |
| Total Debt | 27.10M | 15.60M | 5.02M | 5.14M | 0.00 |
| Total Liabilities | 53.03M | 32.71M | 17.45M | 12.45M | 8.38M |
| Stockholders Equity | 112.05M | 152.34M | 236.20M | 104.52M | 117.96M |
Cash Flow | |||||
| Free Cash Flow | -132.31M | -90.43M | -54.24M | -48.83M | -35.27M |
| Operating Cash Flow | -131.08M | -88.22M | -53.55M | -46.38M | -34.11M |
| Investing Cash Flow | -50.27M | 47.29M | -22.45M | -27.22M | 6.00M |
| Financing Cash Flow | 100.35M | 11.68M | 187.63M | 32.98M | 48.90M |
Cabaletta Bio Technical Analysis
Positive
2.96
Price Trends
2.94
Positive
2.63
Positive
2.30
Positive
Market Momentum
-0.06
Positive
53.27
Neutral
58.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CABA, the sentiment is Positive. The current price of 2.96 is above the 20-day moving average (MA) of 2.95, above the 50-day MA of 2.94, and above the 200-day MA of 2.30, indicating a bullish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 53.27 is Neutral, neither overbought nor oversold. The STOCH value of 58.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CABA.
Cabaletta Bio Risk Analysis
Cabaletta Bio disclosed 86 risk factors in its most recent earnings report. Cabaletta Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cabaletta Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $458.91M | -1.84 | -46.34% | ― | ― | 14.33% | |
55 Neutral | $503.44M | -2.96 | -39.83% | ― | -71.42% | -248.91% | |
52 Neutral | $136.92M | 6.18 | 17.46% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $329.52M | -1.34 | -121.73% | ― | ― | -17.21% | |
47 Neutral | $187.48M | -1.42 | -74.28% | ― | -19.00% | -2.72% | |
44 Neutral | $186.34M | -1.07 | -60.15% | ― | -8.79% | 81.36% |
* Healthcare Sector Average
CABA
Cabaletta Bio
2.96
1.82
159.65%
TNXP
Tonix Pharma
13.90
-3.90
-21.91%
BDTX
Black Diamond Therapeutics
2.39
1.03
75.74%
AVIR
Atea Pharmaceuticals
5.76
2.98
107.19%
CRBU
Caribou Biosciences
1.94
1.18
155.26%
TRDA
Entrada Therapeutics Inc
13.15
4.96
60.56%
Cabaletta Bio Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Cabaletta Bio Updates Rese-cel Programs and Financial Outlook
Positive
Mar 23, 2026
On March 23, 2026, Cabaletta Bio reported fourth-quarter and full-year 2025 results and outlined progress on rese-cel, its lead CAR T therapy for autoimmune diseases. The company said its RESET-Myositis registrational cohort is enrolling 17 dermat...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Cabaletta Bio Sets 2026 Strategy for Rese-cel Expansion
Positive
Jan 12, 2026
On January 12, 2026, Cabaletta Bio outlined its 2026 strategic priorities centered on advancing rese-cel toward registration in myositis and broadening its autoimmune pipeline. The company is actively enrolling a 17‑patient FDA-aligned regis...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.